



OPEN

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

Published online: 03 March 2023

Niki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, Sara Pilotto, Ana Drozdowskyj, Carles Codony-Servat, Ana Giménez-Capitán, Miguel Angel Molina-Vila, Jordi Bertrán-Alamillo, Radj Gervais, Bartomeu Massuti, Teresa Morán, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario García-Campelo, Santiago Viteri, María González-Cao, Daniela Morales-Espinosa, Alberto Verlicchi, Elisabetta Crisetti, Imane Chaib, Mariacarmela Santarpia, José Luis Ramírez, Joaquim Bosch-Barrera, Andrés Felipe Cardona, Filippo de Marinis, Guillermo López-Vivanco, José Miguel Sánchez, Alain Vergnenegre, José Javier Sánchez Hernández, Isabella Sperduti, Emilio Bria & Rafael Rosell

Correction to: *Scientific Reports* <https://doi.org/10.1038/srep17499>, published online 07 December 2015

This Article contains an error in Figure 3A, where the mTOR panel is an inadvertent duplication of the BIM panel.

The corrected Figure 3 and accompanying legend appear below.

In addition, the Supplementary Information file published with this Article contains an error in Supplementary Figure 3A, where the mTOR panel is inadvertently duplicated from the BIM panel. The corrected Supplementary Information file is provided below.




Figure 3. The IC₅₀ values for gefitinib in *EGFR*-mutant lung adenocarcinoma cell lines are associated with basal BIM and mTOR expression (protein or mRNA). (a) mTOR and BIM expression in *EGFR*-mutant lung adenocarcinoma cell lines. Lysates were prepared and run on gels for western blot with specific antibodies. Actin was used as the loading control. Among the three sensitive *EGFR*-mutant lung adenocarcinoma cell lines, H3255, PC-9 and 11-18, 11-18 is the one with the highest mTOR and BIM protein expression. (b) *MTOR* and *BIM* mRNA expression in *EGFR*-mutant lung adenocarcinoma cell lines by qRT-PCR normalized to β -actin. Among the three sensitive *EGFR*-mutant lung adenocarcinoma cell lines, H3255, PC-9 and 11-18, 11-18 has the highest *MTOR* and *BIM* mRNA expression. PC-9, 11-18 and H1975 cells have high *BIM* mRNA expression. H1650 cells have low *BIM* mRNA expression. The two gefitinib resistant *EGFR*-mutant lung adenocarcinoma cell lines, H1975 and H1650, have intermediate and high *MTOR* mRNA expression levels, respectively. Values are the mean \pm standard deviation of triplicate experiments. **BIM* low, < 1.83; *BIM* intermediate, 1.83–2.96; *BIM* high, > 2.96; *MTOR* low, < 0.91; ***MTOR* intermediate, 0.91–1.97; and *MTOR* high, > 1.97. Error bars indicate the standard deviation. (c) The IC₅₀ values for gefitinib increase in the three sensitive *EGFR*-mutant lung adenocarcinoma cell lines, H3255, PC-9 and 11-18, as mTOR expression increases (protein or mRNA). 11-18 are sensitive cells with the highest mTOR expression and IC₅₀ value for gefitinib 0.39 μ M, a concentration more than 100-fold higher compared to H3255 cells that have the lowest mTOR expression and are hypersensitive to gefitinib (IC₅₀ 0.003 μ M).

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-023-30374-9>.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023